The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model
1. Latvian Institute of Organic Synthesis 2. Faculty of Medicine, University of Latvia 3. Latvian Institute of Organic Synthesis
Faculty of Medicine, University of Latvia
Streptozotocin (STZ) was used to induce the diabetic rat model. STZ rats were treated with mildronate (100 mg/kg daily, per os or intraperitoneally for 6 weeks). Body weight, blood glucose, triglyceride, ketone body concentrations, glycated hemoglobin percent (HbA1c%), glucose tolerance, and the development of neuropathic pain were monitored throughout the experiment. In the STZ + mildronate group, mildronate treatment caused a significant decrease in mean blood glucose (on week 4) and triglyceride concentrations (on weeks 3-6), significantly slowed the increase in HbA1c% (on week 6) and improved glucose tolerance 120 minutes after glucose ingestion during oral glucose tolerance test versus the STZ group. Mildronate completely protected development of STZ-induced neuropathic pain from the first administration week up to end of the experiment. The obtained data indicate clinical usefulness of the drug for the treatment of diabetes mellitus and its complications.
Sokolovska J., Rumaks J., Karajeva N., Grinvalde D., Sharipova J., Klusha V., Kalvinsh I., Sjakste N. (2011) The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model. Biomeditsinskaya Khimiya, 57(5), 490-500.
Sokolovska J. et al. The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model // Biomeditsinskaya Khimiya. - 2011. - V. 57. -N 5. - P. 490-500.
Sokolovska J. et al., "The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model." Biomeditsinskaya Khimiya 57.5 (2011): 490-500.
Sokolovska, J., Rumaks, J., Karajeva, N., Grinvalde, D., Sharipova, J., Klusha, V., Kalvinsh, I., Sjakste, N. (2011). The influence of mildronate on peripheral neuropathy and some characteristics of glucose and lipid metabolism in rat streptozotocin-induced diabetes mellitus model. Biomeditsinskaya Khimiya, 57(5), 490-500.
Liepins E., Vilskerts R., Skapare E., Svalbe B., Kuka J., Cirule H., Pugovics O., Kalvins I., Dambrova M. (2008) Life Sci., 83, 613-619. CrossRef Scholar google search
Liepinsh E., Vilskersts R., Zvejniece L., Svalbe B., Skapare E., Kuka J., Cirule H., Grinberga S., Kalvinsh I., Dambrova M. (2009) Br. J. Pharmacol., 157, 1549-1556. CrossRef Scholar google search
Pupure J., Fernandes M.A., Santos M.S., Moreno A.J., Kalvinsh I., Klusa V. Oliveira C.R. (2008) Cell Biochem Funct., 26, 620-631. CrossRef Scholar google search
Klusa V., Pupure J., Isajevs S., Rumaks J., Gordjushina V., Kratovska A., Taivans I., Svirskis S., Viksna L., Kalvinsh I. (2006) Basic Clin. Pharmacol. Toxicol., 99, 323-328. CrossRef Scholar google search
Isajevs S., Pupure J., Gordjushina V., Kratovska A., Taivans I., Viksna L., Kalvinsh I., Klusha V. (2007) Proc. Latvian Acad. Sci. Part B, 6, 26-32. Scholar google search
Runge-Morris M., Vento C. (1995). Drug Metabol. Dispos., 23, 455-459. Scholar google search
McNeill J.H. (1999) Experimental models of diabetes. CRC Press LLC. Scholar google search
Qaseem A., Vijan S., Snow V., J. Cross T., Weiss K., Owens D. (2007) Ann. Intern. Med., 147, 417-422. CrossRef Scholar google search
Schopfer F.J., Lin Y., Baker P.R., Cui T., Garcia-Barrio M., Zhang J., Chen K., Chen Y.E., Freeman B.A. (2005) Proc. Natl. Acad. Sci. USA, 102, 2340-2345. CrossRef Scholar google search
Sjakste N., Kleschyov A.L., Boucher J.L., Baumane L., Dzintare M., Meirena D., Sjakste J., Sydow K., Munzel T., Kalvinsh I. (2004) Eur. J. Pharmacol., 495, 67-73. CrossRef Scholar google search
